Cyted
Cyted is a Cambridge-based medical technology company that combines the FDA-cleared EndoSign® capsule sponge device with molecular biomarker assays and AI-assisted pathology to detect Barrett's Esophagus and esophageal cancer, serving the UK NHS across 70+ hospitals and expanding into US hospital systems.
- Company typePrivate
- Founded2020
- HeadquartersCambridge, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Cyted does
Cyted is a Cambridge, UK-headquartered medical technology company developing the EndoSign® capsule sponge cell collection device combined with proprietary methylation biomarker assays for the non-endoscopic detection of esophageal conditions, primarily Barrett's Esophagus and esophageal adenocarcinoma. The device replaces sedation-dependent endoscopy with a minimally invasive, swallowable capsule that collects pan-esophageal cells in minutes, which are then analyzed in Cyted's laboratories using molecular diagnostics (including TFF3 and methylation biomarkers) and AI-assisted digital pathology screening developed in collaboration with Microsoft Research. Cyted serves public and private healthcare systems, with deep commercial traction across the UK NHS (70+ hospitals and GP surgeries in England, Scotland, Wales, and Northern Ireland, including a national programme in NHS Scotland since 2020) and an emerging US presence built around the FDA 510(k)-cleared EndoSign®, CLIA- and CAP-accredited US laboratory operations, and the DETECT-ME clinical validation study across 18 US sites.
The business model is a fee-for-service diagnostic testing platform: Cyted provides the EndoSign® device to healthcare providers, processes samples through its own accredited laboratories (CAP-accredited US lab, UK lab operations relocated to Huntingdon in 2021), and bills through multi-year contracts negotiated with NHS trusts, SBRI-funded pilots, and commercial agreements with US hospital systems. Revenue streams are anchored by diagnostic testing services and managed laboratory services, with non-dilutive grant funding (SBRI, Innovate UK, Cancer Research UK) supporting clinical pathway development and product extensions such as Eosinophilic Esophagitis testing. Go-to-market combines enterprise field sales to NHS trusts and US hospital systems with clinical evidence generation through peer-reviewed publications (Nature Medicine, Nature Communications, Lancet Oncology), clinical symposiums, and endorsements from ACG and ESGE, supported by senior commercial hires from Guardant Health, Gilead, Agendia, and Medtronic.
Cumulative funding exceeds $73 million across equity (~$44M Series B led by EQT Life Sciences in August 2025, $16.8M Series A co-led by BGF and Morningside in May 2023) and non-dilutive grants. The company employs 51-100 staff across its UK headquarters, R&D/laboratory operations, and US subsidiary Cyted Health Inc., and is led by Co-founder & CEO Marcel Gehrung PhD alongside Co-founders Prof. Rebecca Fitzgerald OBE (Chair of the Scientific Advisory Board) and Dr. Maria O'Donovan (Lead Pathologist), with Board Chair Gail Marcus and US President Betsy Hanna anchoring US commercialization.
Cyted firmographics
Firmographics- Name
- Cyted
- Legal name
- Cyted Ltd.
- Website
- https://cyted.ai
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cyted is a Cambridge-based medical technology company that combines the FDA-cleared EndoSign® capsule sponge device with molecular biomarker assays and AI-assisted pathology to detect Barrett's Esophagus and esophageal cancer, serving the UK NHS across 70+ hospitals and expanding into US hospital systems.
- Ownership category
- akta.pro rank
Cyted industry classification
Industry- Product category
- Esophageal Cancer Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE)
- akta.pro secondary industries
- Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)
Keywords
Where Cyted is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Cyted business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Testing Services: Cyted provides diagnostic testing services through its EndoSign® platform, combining the capsule sponge device with laboratory molecular analysis. Revenue is generated from healthcare providers (NHS, US hospitals) paying for diagnostic tests and services.
- Laboratory Services: Cyted operates laboratories providing molecular diagnostic analysis of samples collected via EndoSign® devices, serving NHS and expanding US operations.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Diagnostic testing services for healthcare providers |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Cyted product offering
Product offeringCore offering
Cyted develops and commercializes the EndoSign® (formerly Cytosponge) capsule sponge cell collection device paired with proprietary methylation biomarker molecular assays and AI-powered digital pathology screening to detect Barrett's Esophagus and esophageal cancer non-endoscopically. The company operates CLIA-certified and CAP-accredited laboratories in the UK and US that process samples collected via the device for NHS trusts, US hospital systems, and clinical research partners.
Differentiator
Problem solved
Functional benefit
Brands
- EndoSign®: Minimally-invasive capsule sponge device for safe and accessible cell collection with full esophageal sampling, combined with advanced molecular diagnostics for detection of Barrett's Esophagus and esophageal cancer prevention.
Products and services
- EndoSign® Cell Collection Device Minimally invasive, non-endoscopic capsule sponge cell collection device (FDA 510(k)-cleared) that enables safe, accessible cell collection with full esophageal sampling for healthcare providers diagnosing esophageal disease.
- Molecular Diagnostic Test for Barrett's Esophagus Proprietary methylation-based molecular assay analyzing esophageal cells collected via EndoSign® to detect Barrett's Esophagus; shown to detect 10x more cases than standard care.
- Molecular Diagnostic Test for Esophageal Neoplasia Molecular assay for detection of esophageal neoplasia and esophageal adenocarcinoma using EndoSign® collected samples, supported by AI/ML pathology screening.
- Eosinophilic Esophagitis (EoE) Testing Platform Non-endoscopic molecular testing platform under development for diagnosing and predicting treatment response for Eosinophilic Esophagitis.
- Heartburn Health Check Programme Diagnostic programme pairing EndoSign® capsule sponge cell collection with molecular analysis to screen patients with chronic GERD/heartburn for Barrett's Esophagus and esophageal cancer in community and primary care settings.
- Cyted Laboratory Services CLIA-certified and CAP-accredited laboratory services providing molecular diagnostic analysis of EndoSign® collected samples for NHS and US healthcare providers, including AI-assisted pathology screening.
Quantifiable outcome
- 78% reduction in demand for endoscopies in secondary care
- +7 more outcomes
Companies that use Cyted
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
Cyted technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Cyted partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and major.
- Devyser Genomic LaboratoriescorePartnership for laboratory analysis of samples collected via EndoSign® device. Established following FDA clearance to support US commercialization.
- Microsoft ResearchcoreCollaboration to develop AI models for efficient screening of cancer cells. Published in Nature Communications, with AI potentially reducing pathologist workload by up to 63%. Research enables large-scale screening of Barrett's esophagus using deep learning.
- University of CambridgecoreCyted was founded by leading experts at the University of Cambridge. Co-founder Prof. Rebecca Fitzgerald serves as Director of the Early Cancer Institute at Cambridge and developed the Cytosponge-TFF3 test from concept through clinical trial.
- MedtronicmajorPartnership for Cytosponge device manufacturing and distribution. Medtronic collaborated on NHS pilot projects including CYTOPRIME and digital pathology initiatives.
- NHS Cancer Programme / SBRI HealthcarecoreNHS Cancer Programme provided £3.4m non-dilutive grant for community testing expansion. SBRI Healthcare grants have funded multiple projects including CYTOPRIME1, CYTOPRIME2, and Wales/Northern Ireland pilots.
- Cancer Research UKcoreLong-standing partnership for research and development. CRUK-funded research led to Cytosponge development. Joint funding for Project DELTA and BEST4 screening trial (jointly funded with NIHR).
- Lancashire and South Cumbria Cancer AlliancemajorNHS partner for CYTOPRIME project demonstrating capsule sponge testing in primary care and community settings across North West England.
- Unity InsightsmajorHealthcare analytics partner that independently evaluated Cyted's technology. Published reports demonstrating 78% reduction in endoscopy demand and significant cost savings.
- Cardiff & Vale UHBmajorWales pilot partner for SBRI Centre of Excellence and Innovation funded project to improve early detection of oesophageal cancer using EndoSign®.
- Belfast Health & Social Care TrustmajorNorthern Ireland pilot partner for SBRI-funded diagnostic pathway demonstrating sustainable model for integrating capsule sponge diagnostics into clinical pathways.
- Western Health & Social Care TrustmajorNorthern Ireland partner in SBRI innovation project for oesophageal cancer early detection implementing EndoSign® testing.
- Professor Rebecca Fitzgerald OBEcoreCo-founder and Chair of Scientific Advisory Board. Professor of Cancer Prevention and Director of the Early Cancer Institute at University of Cambridge. Leading expert in BE and EAC who pioneered minimally invasive cell sampling coupled with biomarker tests.
- Chris Freeman (Strategic Advisor)majorFormer Chief Commercial Officer of Guardant Health and VP at Gilead Sciences. Appointed as strategic advisor to advise on growth and US commercialization.
Scale indicators13 records
Recent moves8 records
Expansion highlights6 records
Cyted competitors and assessment
Company assessmentDirect peers
- Lucid Diagnostics: Lucid's EsoCheck (capsule sponge) and EsoGuard (methylation biomarker) test directly competes with Cyted's EndoSign-plus-methylation platform for non-endoscopic Barrett's Esophagus detection, targeting the same US gastroenterology channel.
- CDx Diagnostics: CDx offers WATS³ (wide-area transepithelial sampling) for Barrett's detection, a competing non-endoscopic or minimally invasive tissue sampling method targeting the same gastroenterologist customer base as Cyted.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Cyted social profiles
Digital presenceCyted financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cyted leadership team
Management profileNumber of profiles
Profiles18 records
Cyted subsidiaries and ownership
Company hierarchySubsidiaries2 records
Cyted funding detail
Funding detailFunding overview
Funding rounds10 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cyted M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cyted
What does Cyted do?
Cyted develops and commercializes the EndoSign® (formerly Cytosponge) capsule sponge cell collection device paired with proprietary methylation biomarker molecular assays and AI-powered digital pathology screening to detect Barrett's Esophagus and esophageal cancer non-endoscopically. The company operates CLIA-certified and CAP-accredited laboratories in the UK and US that process samples collected via the device for NHS trusts, US hospital systems, and clinical research partners.
Is Cyted a public or private company?
Cyted is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cyted founded?
Cyted was founded in 2020. It employs 51 to 100 people.
Where is Cyted based?
Cyted is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Cyted make money?
Two revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are laboratory Services.
Who are Cyted's main competitors?
Direct peers on record are Lucid Diagnostics and CDx Diagnostics.
Does Cyted have an API?
No public API is recorded for Cyted.
What industry is Cyted in?
Cyted's product category is Esophageal Cancer Diagnostics. Its primary akta.pro industry code is HLAHAAAE, Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics), with a secondary code of HLAAALAI, Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays). Its NAICS code is 325413 and its SIC code is 2835.